The IBD risk variant GPR65 I231L impairs receptor function in macrophages, dendritic cells, and T cells, suggesting that an agonist or PAM could be used to tune receptor signaling toward the WT phenotype (17–19, 28, 29). Here, GPR65 is linked to inflammatory bowel disease.